JP6931042B2 - 甲状腺ベータアゴニストの使用 - Google Patents
甲状腺ベータアゴニストの使用 Download PDFInfo
- Publication number
- JP6931042B2 JP6931042B2 JP2019507069A JP2019507069A JP6931042B2 JP 6931042 B2 JP6931042 B2 JP 6931042B2 JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019507069 A JP2019507069 A JP 2019507069A JP 6931042 B2 JP6931042 B2 JP 6931042B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound
- substituted
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)N(C([N+]O*)O)O* Chemical compound CC(C)N(C([N+]O*)O)O* 0.000 description 3
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| US62/326,436 | 2016-04-22 | ||
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515033A JP2019515033A (ja) | 2019-06-06 |
| JP2019515033A5 JP2019515033A5 (enExample) | 2020-06-11 |
| JP6931042B2 true JP6931042B2 (ja) | 2021-09-01 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507069A Active JP6931042B2 (ja) | 2016-04-22 | 2017-04-24 | 甲状腺ベータアゴニストの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (enExample) |
| EP (1) | EP3445373B1 (enExample) |
| JP (1) | JP6931042B2 (enExample) |
| KR (1) | KR102407059B1 (enExample) |
| AU (1) | AU2017252126B2 (enExample) |
| BR (1) | BR112018071586A2 (enExample) |
| CA (1) | CA3021681C (enExample) |
| ES (1) | ES2992773T3 (enExample) |
| MX (1) | MX385085B (enExample) |
| WO (1) | WO2017185087A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| EP3768690B1 (en) * | 2018-03-22 | 2025-08-27 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| JP2007524656A (ja) | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
| EP1689383B1 (en) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| NZ561148A (en) | 2004-12-08 | 2008-12-24 | Sirion Therapeutics Inc | Methods, assays and compositions for treating retinol-related diseases |
| CA2606498C (en) * | 2005-05-26 | 2016-08-09 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| EP1898926A2 (en) | 2005-05-26 | 2008-03-19 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| CN107201364A (zh) | 2011-06-21 | 2017-09-26 | 阿尔尼拉姆医药品有限公司 | 用于抑制载脂蛋白c‑iii（apoc3）基因表达的组合物与方法 |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| WO2016134292A1 (en) | 2015-02-20 | 2016-08-25 | Oregon Health & Science University | Derivatives of sobetirome |
| RU2719245C2 (ru) | 2016-02-29 | 2020-04-17 | Филип Моррис Продактс С.А. | Тара и заготовка с шарнирной крышкой |
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| AU2017252122B2 (en) | 2016-04-22 | 2023-02-09 | Viking Therapeutics, Inc. | Use of Thyroid beta-Agonists |
| CA3024680A1 (en) | 2016-05-18 | 2017-11-23 | Oregon Health & Science University | Derivatives of sobetirome |
-
2017
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3021681C (en) | 2024-09-24 |
| EP3445373A4 (en) | 2019-12-18 |
| KR20190039027A (ko) | 2019-04-10 |
| US11351183B2 (en) | 2022-06-07 |
| US20190321379A1 (en) | 2019-10-24 |
| US11951114B2 (en) | 2024-04-09 |
| KR102407059B1 (ko) | 2022-06-10 |
| MX385085B (es) | 2025-03-14 |
| ES2992773T3 (en) | 2024-12-18 |
| WO2017185087A1 (en) | 2017-10-26 |
| US20220257618A1 (en) | 2022-08-18 |
| MX2018012900A (es) | 2019-07-01 |
| AU2017252126A1 (en) | 2018-11-08 |
| EP3445373B1 (en) | 2024-08-21 |
| BR112018071586A2 (pt) | 2019-02-12 |
| US12440502B2 (en) | 2025-10-14 |
| EP3445373A1 (en) | 2019-02-27 |
| US20250000880A1 (en) | 2025-01-02 |
| CA3021681A1 (en) | 2017-10-26 |
| AU2017252126B2 (en) | 2023-02-09 |
| JP2019515033A (ja) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2669800C2 (ru) | Способы лечения воспаления, аутоиммунных расстройств и боли | |
| US12440502B2 (en) | Use of thyroid beta-agonists | |
| AU2023202321B2 (en) | Use of thyroid beta-agonists | |
| WO2020051322A1 (en) | Methods of treating cytokine release syndrome | |
| JP6010196B2 (ja) | オキサゾリジノン含有二量体化合物、組成物、ならびに作製および使用方法 | |
| JP2022515293A (ja) | クロモリンエステルおよびそれらの使用 | |
| JP7019585B2 (ja) | 核酸プロドラッグ | |
| JP2020536853A (ja) | 転写因子ｓａｌｌ４の小分子阻害およびその使用 | |
| HK40064933A (en) | Use of thyroid beta-agonists | |
| HK40013781A (en) | Use of thyroid beta-agonists | |
| HK40013781B (zh) | 甲状腺β-激动剂的应用 | |
| HK40007271A (en) | Use of thyroid beta-agonists | |
| CN108289899A (zh) | 采用葡萄糖生成的抑制剂的联合疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20190920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200424 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210524 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210713 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210812 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6931042 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |